ACK900 is a first-in-class Therapeutic N-Glycan Modulation Platform that reprograms tumor stroma and fibrotic tumor microenvironments through precision N-glycan modulation. By overcoming “Universal Stromal Resistance,” ACK900 converts therapy-resistant “stromal fortress tumors” into “therapy-permissive tumors,” enabling enhanced combination therapy and anti-metastatic efficacy across fibrosis-associated solid tumors.

ACK900 combines Natural Product-Inspired Combinatorial Chemistry (NPICC) with precision N-glycan modulation to establish a first-in-class Therapeutic N-Glycan Modulation Platform. Unlike non-selective α-mannosidase inhibitors such as Swainsonine, ACK900 selectively targets Golgi α-mannosidase II to remodel tumor stroma and fibrotic tumor microenvironments. ACK900 suppresses metastasis, modulates CAF-related signaling, and overcomes Universal Stromal Resistance in fibrosis-associated solid tumors

ACK900 is a first-in-class Therapeutic N-Glycan Modulation Platform that reprograms tumor stroma and fibrotic microenvironments through precision N-glycan modulation. By overcoming Universal Stromal Resistance, ACK900 enhances drug penetration, suppresses metastasis, and improves chemotherapy, targeted therapy, and immunotherapy efficacy. The platform has translational and commercial potential for stromal-resistant solid tumors, including PDAC, HCC, TNBC, gastric, and lung cancers.